Fresenius SE's restructuring and dividend reinstatement signal strong growth. Read why FSNUF stock may not be a long-term buy ...

Kepler Capital analyst Oliver Reinberg maintained a Buy rating on Fresenius SE & Co. KGaA (0OO9 – Research Report) on March 13 and set a ...

Kepler Capital analyst Oliver Reinberg maintained a Hold rating on Fresenius Medical Care AG & Co. KGaA (0H9X – Research Report) on March ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...

The banker added: “Volatility will be higher for longer, and that can only help in the convertible space. The higher the ...

Celltrion and Formycon with Fresenius Kabi launched their respective ustekinumab biosimilars (Steqeyma and Otulfi), joining 4 ...

On March 7, 2025, the District Court for the District of New Jersey entered a Stipulation and Order of Dismissal Without Prejudice in view of ...

The US Supreme Court on Monday declined to review a Fresenius Kabi USA LLC scientist’s claim that she faced discrimination ...

We came across a bullish thesis on Fresenius Medical Care AG (NYSE:FMS) on ValueInvestorsClub by mimval. In this article, we ...

Fresenius, the German health care group, sold 3.6% of the shares in kidney dialysis provider Fresenius Medical Care on Monday ...

Gain insight on Fresenius, Clarity and more in the latest Market Talks covering ...

The FDA had approved Otulfi in September 2024 to treat Crohn’s disease, ulcerative colitis, psoriasis and active psoriatic arthritis. Information on pricing is not yet available.